Investigations on the time dependance of platelet functions I. General methodical investigations

Réuter, H.; Podolsak, B.; Hagen, Inger; Linker, H; Ströder, J; Gross, R.

doi:10.1016/0049-3848(73)90056-x

Cited by 13 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include the anticoagulant used, the pH, the time of storage, physical properties of the stirbar, and the platelet count. 55,70,238,245,261 In addition, a major limitation of platelet aggregation studies is the lack of standardization of techniques of reporting of results, making it difficult to compare data from different laboratories. 232 For example, some investigators established a minimal threshold concentration of various platelet aggregating agents, whereas others analyze and compare the curves of light transmission induced by fixed concentration of aggregating agents or develop dose-response curves.…”

Section: Platelet Aggregationmentioning

confidence: 99%

Platelet Consumption in Cardiovascular Disease

Ag¹,

Ac²,

Genton³

1982

Semin Thromb Hemost

View full text Add to dashboard Cite

Many tests have been devised to investigate the role of platelets in arterial or venous thromboembolism. The mechanisms of platelet reactivity that the tests have measured have been variable and the early studies have been of little value in determining the contribution of platelet consumption in thromboembolic diseases. More recently, tests of in vivo platelet release and of platelet survival and turnover have been introduced and thought to be of great potential in the investigation of thromboembolic disorders. However, the data published thus far using more tests are far from conclusive that platelet activation and consumption occurs in thromboembolic disorders associated with arteriosclerosis. It may be that they are neither sensitive nor specific enough to detect minor changes in platelet activation. There is, however, some consistency that in conditions involving the larger vessels, prosthetic surfaces, or in association with active and recurrent venous thromboembolism, platelet release and platelet consumption measured by platelet survival time may occur. In particular, the abnormal results are consistently found in acute and recurrent venous thromboembolism, cardiac valve replacement with the older prosthetic devices, and arteriosclerosis of the larger arteries with clinical episodes of thromboembolism. However, in coronary artery disease, cerebrovascular disease, and peripheral vascular disease, the data are inconclusive, probably because the tests lack sensitivity. In addition, the value of the tests in the management of patients with thromboembolic disorders appears to be limited.

show abstract

Section: Platelet Aggregationmentioning

confidence: 99%

Platelet Consumption in Cardiovascular Disease

Ag¹,

Ac²,

Genton³

1982

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Recently a time-dependent increase in responsiveness after incubation at 37°C to epinephrine and collagen also has been reported (16). The increment in ADP response has been attributed to alteration of platelet membrane permeability with associated leakage of ADP into the plasma (17).…”

Section: Discussion -mentioning

confidence: 99%

Effect of phentolamine on platelet aggregation in patients with pheochromocytoma

Zweifler¹,

Romero²

1975

Thrombosis Research

View full text Add to dashboard Cite

Since exogeneous catecholamines potentiate ADP-induced aggregation in vitro, and this effect is blocked directly by phentolamine, it was assumed that platelets from patients with pheochromocytoma would be unusually sensitive to ADP and that this sensitivity would be reduced in the presence of phentolamine. Findings in four patients with pheochromocytoma were compared to results in 20 normals. Phentolamine had no immediate effect in either group. Pheochromocptoma platelets became more responsive to ADP after standing and this increase in responsiveness was inhibited by phentolamine. These results: 1) suggest that catecholamine concentrations in the plasma of patients with pheochromocytoma are not high enough to potentiate ADP aggregation and 2) may be explained by assuming that pheochromocytoma platelets are saturated with catecbolamines.

show abstract

“…Numerous variables may affect platelet aggregation, including the anticoagulant used, the pH [24,53,64,66,69,90], time of storage [64], the rate of stirring, the shape and size of the stir bar [21], concentration of the platelets and the size and shape of the cuvette. As already pointed out, many drugs may affect platelet aggregation.…”

Section: Platelet Aggregationmentioning

confidence: 99%